Former SkyePharma CEO and current Executive Chairman of PolyTherics Ken Cunningham has joined the Board of Directors of inhaled drug developer Prosonix as a Non-Executive Director. Cunningham will also serve as Chair of the Prosonix Advisory Board.
Prosonix is developing several inhaled therapies for asthma and COPD based on its proprietary particle engineering technologies. Its pipeline includes drug-only formulations of fluticasone proprionate and glycopyrrolate, as well as formulations that combine fixed ratios of different drug molecules within each particle.
Board Chairman Jim Phillips said of the appointment: “We are very pleased to welcome Ken to the board at this exciting stage in the Company’s development. Ken brings a wealth of experience in respiratory drug development and we very much look forward to his strategic advice and input as we invest the proceeds from our recent £11.4 million fund raising to generate key performance and clinical data for our lead respiratory drug candidates.”
Cunningham commented, “The global market for respiratory medicines is entering a period of transition as many leading blockbuster products approach the end of their patents. Complex manufacturing challenges mean that new products need to demonstrate significant performance advantages in order to take their place. Prosonix has the unique approach of developing respiratory medicines based on ‘smart’ particles whose fundamental properties are designed for delivery, using simple inhalation devices, to the parts of the respiratory system where they can elicit the optimal clinical effect. I am very much looking forward to working with the company during this exciting phase of its growth.”
Read the Prosonix press release.
